• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直接口服抗凝剂达比加群和利伐沙班对家兔血液凝固功能的影响。

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits.

作者信息

Yin Lu, Qi Yuan, Ge Zhiru, Li Jiajin

机构信息

Department of Cardiology, Gongli Hospital of Shanghai Pudong New Area, Shanghai 200000, China.

Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

出版信息

Open Life Sci. 2022 Jan 28;17(1):1-9. doi: 10.1515/biol-2022-0002. eCollection 2022.

DOI:10.1515/biol-2022-0002
PMID:35128064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8800383/
Abstract

The aim of this study was to explore the effects of dabigatran and rivaroxaban on the activities of various coagulation factors. To achieve that, 60 rabbits were randomly divided into experimental groups that received different doses of dabigatran or rivaroxaban. The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed. In the dabigatran groups, activated partial thromboplastin time and thromboplastin time (TT) were prolonged after drug administration, and the activities of FII, FV, FVIII, and FX were inhibited as the drug concentration increased. Low doses of dabigatran inhibited APC activity. In the rivaroxaban groups, APTT and TT were not significantly prolonged after drug administration. In contrast, the high-dose rivaroxaban group exhibited prolonged PT, and the degree of inhibition of the activities of FII, FV, FVIII, and FX increased as the drug concentration increased. Rivaroxaban had no significant effect on APC activity regardless of dosage. As the drug concentration increased, both NOACs had more significant inhibitory effects on the activities of FII, FV, FVIII, and FX. Low concentrations of dabigatran generated an inhibitory effect on APC activity, while high concentrations of dabigatran had no significant effect. Rivaroxaban had no significant effect on APC activity.

摘要

本研究的目的是探讨达比加群和利伐沙班对各种凝血因子活性的影响。为此,将60只兔子随机分为接受不同剂量达比加群或利伐沙班的实验组。分析了达比加群和利伐沙班对凝血因子II、V、VIII、X及活化蛋白C(APC)活性的影响。在达比加群组中,给药后活化部分凝血活酶时间和凝血酶时间(TT)延长,随着药物浓度增加,凝血因子II、V、VIII和X的活性受到抑制。低剂量达比加群抑制APC活性。在利伐沙班组中,给药后活化部分凝血活酶时间和凝血酶时间未显著延长。相反,高剂量利伐沙班组的凝血酶原时间延长,随着药物浓度增加,凝血因子II、V、VIII和X活性的抑制程度增加。利伐沙班对APC活性无论剂量大小均无显著影响。随着药物浓度增加,两种非维生素K拮抗剂对凝血因子II、V、VIII和X活性的抑制作用更显著。低浓度达比加群对APC活性产生抑制作用,而高浓度达比加群无显著影响。利伐沙班对APC活性无显著影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/f54e973e3ad7/j_biol-2022-0002-fig004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/8705be691f0c/j_biol-2022-0002-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/08841c73933a/j_biol-2022-0002-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/dc9b01cf88e9/j_biol-2022-0002-fig003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/f54e973e3ad7/j_biol-2022-0002-fig004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/8705be691f0c/j_biol-2022-0002-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/08841c73933a/j_biol-2022-0002-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/dc9b01cf88e9/j_biol-2022-0002-fig003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c1/8800383/f54e973e3ad7/j_biol-2022-0002-fig004.jpg

相似文献

1
Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits.直接口服抗凝剂达比加群和利伐沙班对家兔血液凝固功能的影响。
Open Life Sci. 2022 Jan 28;17(1):1-9. doi: 10.1515/biol-2022-0002. eCollection 2022.
2
PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、凝血酶时间(TT)以及达比加群和利伐沙班的止血安全阈值。
Ann Biol Clin (Paris). 2016 Aug 1;74(4):457-64. doi: 10.1684/abc.2016.1173.
3
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.达比加群和利伐沙班对常规凝血检测的影响。一项比利时全国性调查。
Thromb Haemost. 2015 Jan;113(1):154-64. doi: 10.1160/TH14-02-0161. Epub 2014 Sep 18.
4
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.直接口服抗凝剂治疗期间的紧急凝血评估:局限性与解决方案
Stroke. 2017 Sep;48(9):2457-2463. doi: 10.1161/STROKEAHA.117.017981. Epub 2017 Aug 3.
5
Anticoagulant Activities of Indobufen, an Antiplatelet Drug.吲哚布芬的抗凝血活性,一种抗血小板药物。
Molecules. 2018 Jun 15;23(6):1452. doi: 10.3390/molecules23061452.
6
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.非维生素K口服抗凝剂抗凝活性的实验室测定
J Am Coll Cardiol. 2014 Sep 16;64(11):1128-39. doi: 10.1016/j.jacc.2014.05.065.
7
Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves.利伐沙班和达比加群对人主动脉狭窄瓣膜内局部凝血和炎症因子表达的影响。
Vascul Pharmacol. 2020 Jul;130:106679. doi: 10.1016/j.vph.2020.106679. Epub 2020 May 7.
8
Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?非瓣膜性心房颤动患者在达比加群和利伐沙班治疗下的常规凝血检测:一种经济且可靠的策略?
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619835053. doi: 10.1177/1076029619835053.
9
Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.用于评估直接口服抗凝剂药效学抗凝作用的即时检验凝血检测
Ther Drug Monit. 2014 Oct;36(5):624-31. doi: 10.1097/FTD.0000000000000064.
10
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.即时检测在直接口服抗凝剂治疗患者的紧急凝血评估中的应用。
Crit Care. 2017 Feb 15;21(1):32. doi: 10.1186/s13054-017-1619-z.

引用本文的文献

1
Dabigatran attenuates methotrexate-induced hepatotoxicity by regulating coagulation, endothelial dysfunction, and the NF-kB/IL-1β/MCP-1 and TLR4/NLRP3 signaling pathways.达比加群通过调节凝血、内皮功能障碍以及NF-κB/IL-1β/MCP-1和TLR4/NLRP3信号通路减轻甲氨蝶呤诱导的肝毒性。
Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):5129-5145. doi: 10.1007/s00210-024-03567-w. Epub 2024 Nov 11.

本文引用的文献

1
Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.直接口服抗凝剂与维生素 K 拮抗剂在预防和治疗房颤患者中风方面的严重出血风险:系统评价和网络荟萃分析。
Cardiovasc Drugs Ther. 2023 Apr;37(2):363-377. doi: 10.1007/s10557-021-07232-9. Epub 2021 Aug 26.
2
Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.目标药物校准的抗 Xa 活性检测及亚洲人群的预期峰谷水平:一项多中心研究。
Am J Cardiovasc Drugs. 2021 Nov;21(6):669-679. doi: 10.1007/s40256-021-00479-5. Epub 2021 Jun 18.
3
Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: and evaluation.
壳聚糖笼状脂质体提高利伐沙班口服生物利用度的研究:制剂制备与评价。
Pharm Dev Technol. 2021 Mar;26(3):316-327. doi: 10.1080/10837450.2020.1870237. Epub 2021 Jan 6.
4
Direct oral anticoagulants: evidence and unresolved issues.直接口服抗凝剂:证据与未决问题。
Lancet. 2020 Nov 28;396(10264):1767-1776. doi: 10.1016/S0140-6736(20)32439-9.
5
Stroke prevention strategies in high-risk patients with atrial fibrillation.高危房颤患者的卒中预防策略。
Nat Rev Cardiol. 2021 Apr;18(4):276-290. doi: 10.1038/s41569-020-00459-3. Epub 2020 Oct 27.
6
An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.一种工程化的因子 Va 通过不同机制预防直接作用的口服抗凝剂引起的出血。
Blood Adv. 2020 Aug 11;4(15):3716-3727. doi: 10.1182/bloodadvances.2020001699.
7
Trends in Stroke Recurrence in Mexican Americans and Non-Hispanic Whites.墨西哥裔美国人和非西班牙裔白种人中风复发的趋势。
Stroke. 2020 Aug;51(8):2428-2434. doi: 10.1161/STROKEAHA.120.029376. Epub 2020 Jul 16.
8
The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays.直接口服抗凝药物(DOACs)对实验室检测的影响及其通过活性炭清除以限制对功能检测的干扰。
Int J Lab Hematol. 2020 Jun;42 Suppl 1:41-48. doi: 10.1111/ijlh.13196.
9
Novel antithrombotic strategies for treatment of venous thromboembolism.新型抗血栓策略治疗静脉血栓栓塞症。
Blood. 2020 Jan 30;135(5):351-359. doi: 10.1182/blood.2019000919.
10
Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.依达鲁珠单抗可完全恢复达比加群酯改变的血小板和纤维蛋白成分的止血作用,而促凝血药物则不能。
Transfusion. 2019 Jul;59(7):2436-2445. doi: 10.1111/trf.15259. Epub 2019 Apr 4.